Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2005-01-10
2010-06-29
Chen, Stacy B (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S199100
Reexamination Certificate
active
07744902
ABSTRACT:
Recombinant respiratory syncytial virus (RSV) having the position of genes shifted within the genome or antigenome of the recombinant virus are infectious and attenuated in humans and other mammals. Gene shifted RSV are constructed by insertion, deletion or rearrangement of genes or genome segments within the recombinant genome or antigenome and are useful in vaccine formulations for eliciting an anti-RSV immune response. Also provided are isolated polynucleotide molecules and vectors incorporating a recombinant RSV genome or antigenome wherein a gene or gene segment is shifted to a more promoter-proximal or promoter-distal position within the genome or antigenome compared to a wild type position of the gene in the RSV gene map. Shifting the position of genes in this manner provides for a selected increase or decrease in expression of the gene, depending on the nature and degree of the positional shift. In one embodiment, RSV glycoproteins are upregulated by shifting one or more glycoprotein-encoding genes to a more promoter-proximal position. Genes of interest for manipulation to create gene position-shifted RSV include any of the NS1, NS2, N, P, M, SH, M2(ORF1), M2(ORF2), L, F or G genes or a genome segment that may be part of a gene or extragenic. A variety of additional mutations and nucleotide modifications are provided within the gene position-shifted RSV of the invention to yield desired phenotypic and structural effects.
REFERENCES:
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4800078 (1989-01-01), Prince et al.
patent: 4800478 (1989-01-01), Takahashi
patent: 5922326 (1999-07-01), Murphy et al.
patent: 5993824 (1999-11-01), Murphy et al.
patent: 6264957 (2001-07-01), Collins
patent: 6689367 (2004-02-01), Collins et al.
patent: 6699476 (2004-03-01), Collins et al.
patent: 6713066 (2004-03-01), Collins et al.
patent: WO 93/21310 (1993-10-01), None
patent: WO 97/06270 (1997-02-01), None
patent: WO 97/12032 (1997-04-01), None
patent: WO 98/02530 (1998-01-01), None
patent: WO 00/61737 (2000-01-01), None
patent: WO 01/04271 (2001-01-01), None
patent: WO 01/04321 (2001-01-01), None
patent: WO 01/04335 (2001-01-01), None
Collins et al. PNAS USA, 1995, 92:11563-11567.
Tang et al. J. Virology, 2001, 75(23):11328-11335.
Buchholz Ursula
Collins Peter L.
Krempl Christine D.
Murphy Brian R.
Whitehead Stephen S.
Chen Stacy B
The United States of America as represented by the Department of
Woodcock & Washburn LLP
LandOfFree
Respiratory syncytial virus vaccines expressing protective... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Respiratory syncytial virus vaccines expressing protective..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Respiratory syncytial virus vaccines expressing protective... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4250136